

BioVersys – executive interview

In this interview, we speak with Dr Marc Gitzinger, founder and CEO of [BioVersys](#), about the strong momentum across the company's antibiotics pipeline and the milestones shaping its next phase of growth. Marc discusses the advancement of lead candidate BV100 into the global Phase III RIV-TARGET trial for carbapenem-resistant *Acinetobacter baumannii* (CRAB) infections, the strategic significance of the China bridging study and how the parallel Phase IIb RIV-CARE study could provide important early clinical insights. He also shares the latest progress on alpibectir, the company's GSK-partnered tuberculosis asset, and explains how BioVersys is leveraging strategic partnerships to maximise the value of its portfolio. Finally, Marc discusses the evolving competitive landscape in antimicrobial resistance, the company's commercialisation strategy and the key clinical, regulatory and business development catalysts investors should watch as BioVersys continues to execute on its growth strategy.

